妙佑医疗国际与Personalis Inc.合作扩大癌症基因组检测
Mayo Clinic妙佑医疗国际(Mayo Clinic)于10月12日星期二宣布了一项协议,允许其向选择参与的癌症患者提供临床级的全面癌症基因组测序。检测结果将提供给患者及其医疗服务提供者,以指导治疗决策、推进癌症研究,并用于支持新诊断测试和癌症治疗的疗法开发。
妙佑医疗国际(Mayo Clinic)于10月12日星期二宣布了一项协议,允许其向选择参与的癌症患者提供临床级的全面癌症基因组测序。检测结果将提供给患者及其医疗服务提供者,以指导治疗决策、推进癌症研究,并用于支持新诊断测试和癌症治疗的疗法开发。
مدينة روتشستر، ولاية مينيسوتا، ومينلو بارك، ولاية كاليفورنيا- أعلنت مايو كلينك عن اتفاقية يوم الثلاثاء، 12 تشرين الأول/أكتوبر، ستسمح لها بتقديم تسلسل جينومي شامل للسرطان من الدرجة السريرية لمرضى السرطان الذين يختارون المشاركة.
Philanthropists Richard and Carol Dean Hertzberg have committed $2.1 million to develop and maintain the Dean-Hertzberg Breast Cancer Database System Initiative at UC San Diego Health Moores Cancer Center to support the work of Anne Wallace, MD and her collaborators at Moores Cancer Center.
a Mayo Clinic anunciou na terça-feira, 12 de outubro, um acordo que lhe permitirá oferecer sequenciamento genômico oncológico abrangente de uso clínico para os pacientes portadores da doença que decidirem participar.
Mayo Clinic anunció un acuerdo el martes 12 de octubre que le permitirá ofrecer secuenciación genómica integral del cáncer de grado clínico a pacientes con cáncer que decidan participar.
Researchers at Moffitt Cancer Center are trying to improve the personalization of radiation therapy through computer modeling. In a new study published in the journal Neoplasia, they model how interactions between cancer cells and immune cells, and their subsequent responses to radiation, impact the tumor. They propose their model may help to predict how patients respond to radiation therapy.
UC San Diego researchers report that conducting genomic evaluations of advanced malignancies can be effective in guiding first-line-of-treatment, rather than waiting until standard-of-care therapies have failed.
Researchers at UC San Diego School of Medicine awarded $11.7 million by National Institutes of Health to identify genomic and socioeconomic factors contributing to health and disease in admixed individuals. The new center aims to bring the genomic revolution to all.
Mayo Clinic announced an agreement on Tuesday, Oct. 12 that will allow it to offer clinical-grade comprehensive cancer genomic sequencing to cancer patients who choose to participate. Test results will be available to patients and their treating health care providers to guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment.
An international team of researchers has developed an algorithm that enhances the ability to compare tumors between different patients, overcoming high inter-patient variability. Although the researchers tested the algorithm on leukemia tumors, they believe that it will also be relevant for other cancer types.
A recently released paper from the Department of Physiology and Sanders-Brown Center on Aging at the University of Kentucky College of Medicine suggests that your genetics can influence your response to Alzheimer’s disease pathology.
A new study from Washington University School of Medicine in St. Louis estimates that 78% to 92% of lung cancers in patients who have never smoked can be treated with precision drugs already approved by the Food and Drug Administration to target specific mutations in a patient’s tumor.
In three Science papers, UC San Diego and UC San Francisco researchers mapped out how hundreds of gene mutations involved in cancer affect the discrete groups of proteins that are the ultimate actors behind the disease. The work points the way to identifying new precision treatments.
Mount Sinai researchers have developed a therapy that shows promise against a deadly pediatric leukemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September.
MD Anderson and Siemens Healthineers have announced the collaborative development of an education program focused on enabling the implementation of consistent, high-quality MRI in radiation oncology.
A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
MD Anderson and BostonGene today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures.
The outlook for patients diagnosed with breast cancer has been changing for the better over time thanks to surgical advances, clinical trials & a more personalized treatment approach. Dr. Lindsay Potdevin, surgical oncologist at Rutgers Cancer Institute of New Jersey, shares how these advances are improving the lives of patients.
While overall cancer cases are declining, they are on the rise in older adolescents and young adults. Today, Memorial Sloan Kettering Cancer Center (MSK) announces the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers (the Stuart Center), dramatically expanding MSK’s already robust efforts to address the very specific, and often unmet, needs of this patient population.
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
Two studies led by Washington University School of Medicine in St. Louis describe the potential of liquid biopsies to identify and track tumor growth in two very different cancers: bladder cancer and peripheral nerve tumors.
Scientists at Children’s Hospital Los Angeles have been paying close attention to the behavior of SARS-CoV-2, since the beginning of the pandemic.
Sbarro Health Research Organization (SHRO) Founder and Director, Antonio Giordano, M.D., Ph.D., of Temple University and the University of Siena, Italy, is part of the GYNOCARE COST Action (CA18117) chaired by Prof Jean Calleja Agius of the University of Malta.
With the goal of dramatically accelerating discoveries in health and disease, Beth Israel Deaconess Medical Center has opened a Spatial Technologies Unit, the first center in Massachusetts and one of the first of its kind worldwide. The new space will provide access to ground-breaking technologies that allow scientists to examine cells as they function within intact tissues. Made possible by a grant from the Massachusetts Life Sciences Center, the BIDMC unit will be a nexus of the state’s precision medicine community, empowering researchers across healthcare, academia, research and industry.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
• Catalyzing gift will support precision medicine efforts at Harvard Medical School and Clalit Research Institute in Israel through data science, clinical research, and training. • Work marks first-of-its-kind collaboration between Harvard Medical School and an Israeli health care system. • Collaboration melds Harvard Medical School’s and Clalit’s capabilities in computational biomedicine and big-data analysis.
Building on prior success combining Cyclin-Dependent Kinase (CDK) inhibitors with hormone therapy to treat breast cancer, researchers are now exploring the potential integration of CDK inhibitors with radiotherapy in a paper issued in the International Journal of Molecular Sciences.
A new cancer immunotherapy pairs ultrasound with specially engineered CAR T cells to destroy malignant tumors while sparing normal tissue. The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.
CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries. Eligible rheumatology registry patients will contribute biological specimens that will be linked to longitudinal provider reported clinical and patient reported outcomes.
A survey of participants in a clinical trial for CommunityRx, a community resource referral intervention, found that nearly half of users reported sharing their personalized health resources with at least one other person.
Researchers from Cleveland Clinic, Case Western Reserve University School of Medicine, and Moffitt Cancer Center have found that the genomic adjusted radiation dose (GARD) may be used to personalize radiotherapy (RT) to maximize the therapeutic effect of a given physical RT dose. This research was published Aug. 4 in The Lancet Oncology journal.
New research by McMaster University evolutionary biologist Rama Singh suggests there is a layer hidden in our cells that controls how genes interact, and how the many billions of possible combinations produce certain results.
الشقيقة (الصداع النصفي) يصيب الملايين من الناس حول العالم. ومع ذلك، فإن تحديد دواء وقائي فعال- أي الأدوية المتاحة فقط بوصفة طبية والأكثر شيوعًا للمصابين بالشقيقة- يظل عملية طويلة ومعقدة. غالبًا ما يتنقل المرضى بين الأدوية لأسابيع أو شهور حتى تتحقق استجابة علاجية.
Enxaquecas atormentam milhões de pessoas em todo o mundo.No entanto, encontrar um medicamento preventivo eficaz, um medicamento mais comumente prescrito para pessoas com diagnóstico de enxaqueca, continua sendo um processo longo e complexo.
偏头痛困扰着全世界数百万人。然而,确定一种有效的预防药物 ― 偏头痛患者最常用的处方药 ― 仍然是一个漫长而复杂的过程。患者通常连续用药数周或数月,才能出现治疗反应。
Las migrañas acosan a millones de personas en todo el mundo. Sin embargo, aún es un proceso largo y complejo el identificar con precisión un medicamento profiláctico (o fármaco más frecuentemente recetado a personas diagnosticadas con migrañas) que surta efecto.
Irvine, Calif., Aug. 2, 2021 — From cutting-edge research for advancing precision medicine to an innovative new effort for improving public water infrastructure to increase conservation, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world. And their impact keeps growing.
The Association for Molecular Pathology (AMP) today released recommendations to support and facilitate sharing of variant data through the use of public repositories.
MD Anderson and Blueprint Medicines announced a three-year strategic collaboration to accelerate the development of BLU-222, an investigational targeted therapy against CDK2.
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells. The platform, which uses a three-dimensional environment to more closely mirror a tumor microenvironment, is demonstrated in research published in Communications Biology.
Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer.
Daniel Catenacci, MD, a physician-scientist and associate professor of medicine at UChicago Medicine, has received the National Cancer Institute (NCI) 2021 Cancer Clinical Investigator Team Leadership Award (CCITLA).
A novel therapeutic may halt rapid kidney function in some type 1 diabetic kidney disease patients.
Researchers at UC San Diego Altman Clinical and Translational Research Institute have received $3 million to create a precision, community-based program to address specific health problems related to adverse childhood experiences that contribute to childhood obesity among Latinos.
As iniciativas de medicina individualizada se concentram principalmente nas doenças raras ou no câncer. Pouco foi tentado para individualizar o tratamento de doenças crônicas não transmissíveis, como a obesidade, uma doença crônica recorrente e uma causa primária de diabetes tipo 2, gordura hepática, doenças cardiovasculares e câncer.
Las iniciativas de la medicina personalizada se concentran, principalmente, en las enfermedades raras o en el cáncer. Han sido escasos los intentos por personalizar el tratamiento de enfermedades crónicas no contagiosas, como la obesidad, que es una afección crónica y recurrente, además de causa principal para diabetes tipo 2, hepatopatía grasa, enfermedad cardiovascular y cáncer.